Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)

ConditionFSHD
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity of Kansas Medical Center

About this trial

The primary goal of this proposal is to collect motor and functional outcomes specific to FSHD over time. By collecting measures specific to FSHD, this will help ensure the best level of clinical care is being provided. Also, the hope is to speed up drug development by gaining a better understanding of how having FSHD impacts motor function and other health outcomes (i.e. breathing, wheelchair use, etc.) and how big a change in motor function would be clinically meaningful to those with FSHD.

Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD) will have approximately 450 FSHD participants followed for a minimum of 3 years. A subset of MOVE FSHD participants, approximately 200, will participate in the MOVE+ sub-study which includes whole body MRI and reachable workspace, as well as optional muscle biopsy and wearable device (US participants only).

Eligibility criteria

Qualifiers

Genetically confirmed FSHD (types 1 or 2) or clinical diagnosis of FSHD with characteristic findings on exam and an affected parent or offspring.

Disqualifiers

Unwilling or unable to provide informed consent.

Any other medical condition which in the opinion of the investigator would interfere with study participation.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

450 Participants
are grouped into 1 trial group

Sponsors and collaborators

University of Kansas Medical Center

Lead sponsor

FSHD Society, Inc.

Collaborator

Friends Research Institute, Inc.

Collaborator

University of Rochester

Collaborator

University of Nevada, Reno

Collaborator

FSHD Canada

Collaborator

Avidity Biosciences, Inc.

Collaborator

AMRA Medical

Collaborator

Seattle Children's Hospital

Collaborator

Dyne Therapeutics

Collaborator

Hoffmann-La Roche

Collaborator

Springbok Analytics

Collaborator

Novartis Pharmaceuticals

Collaborator